about
Environmental and occupational causes of cancer: new evidence 2005-2007Molecular Targeted Therapies of Aggressive Thyroid CancerEndocrine-disrupting chemicals: associated disorders and mechanisms of actionTrends in incidence of childhood cancer in Australia, 1983-2006.The role of the PAX8/PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancerAdalimumab safety in global clinical trials of patients with Crohn's disease.Mechanisms regulating enhanced human leukocyte antigen class II-mediated CD4 + T cell recognition of human B-cell lymphoma by resveratrolSurvey on childhood solid malignant tumors in cases admitted to mofid pediatric hospital from 1996-2010: a single-center studyResidual-QSAR. Implications for genotoxic carcinogenesisEvaluating Changes in the Prevalence of the Autism Spectrum Disorders (ASDs)Trend Analysis of Cancer Mortality and Incidence in Panama, Using Joinpoint Regression Analysis.Lead, calcium uptake, and related genetic variants in association with renal cell carcinoma risk in a cohort of male Finnish smokers.Incidence and Trend of Childhood and Adolescent Cancers in Yazd, Iran.NFAT1 Directly Regulates IL8 and MMP3 to Promote Melanoma Tumor Growth and Metastasis.Body size and renal cell cancer incidence in a large US cohort studyOutcome of patients with esophageal cancer: a nationwide analysis.Primary bladder preservation treatment for urothelial bladder cancer.Longitudinal and circumferential resection margin in adenocarcinoma of distal esophagus and cardia.The effect of a novel frizzled 8-related antiproliferative factor on in vitro carcinoma and melanoma cell proliferation and invasion.Incidence of cutaneous malignant melanoma in Iranian provinces and American states matched on ultraviolet radiation exposure: an ecologic study.The anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth.Cancer in childhood, adolescence, and young adults: a population-based study of changes in risk of cancer death during four decades in Norway.Sorafenib in the treatment of thyroid cancer.
P2860
Q24644043-4043E9F7-A075-4CD5-8A21-C5C4BDDA9E00Q26774734-D45950CF-16E0-480C-AA6F-F75E2BEE8EC3Q28388657-B9F09302-F584-47B0-A0C9-0404794B1265Q33658579-CC0BBFE3-E3F7-49CF-BE5D-F042003DFD98Q33770842-98396891-5613-4864-B97A-5D706A1D0FCCQ34607547-5C9A884A-0901-4D78-B655-A56E7E1FA2A4Q34870725-C24F3B96-5C33-44B8-8520-CA39669F0D9DQ34987093-14CB5CA8-3092-4865-B636-2E8F4E752EC7Q35122062-C8DC9579-476B-4FEC-BD75-18B89E1AA0CBQ35904687-DBD7D826-DB68-494D-8486-963C5C3FB4B9Q36194467-A76212BA-F8EF-4954-983D-C73750663C9DQ36697453-EE9CA27C-2419-4860-AFC4-A340346AE1BEQ36901701-0376742F-ECA6-4195-BC32-7C0F96C95677Q36963684-C66304B2-3EC1-417C-900C-0405295C155BQ37306225-CB0C71D3-3818-43FF-8D38-A45A1D3690EDQ38092688-8ADD6329-B3FE-4E40-BCBF-BC19C708FAFAQ38118058-351EDA9E-24D8-4D11-ACBB-D1A7A341ED50Q38209608-960000D6-0114-4AC1-9D3E-3A6A83BF0740Q39471271-F4D11F19-EFAD-4A0A-879B-C6B0345F95E6Q47309637-92BCF4DE-DF07-484A-B09C-08C1ACDE9DFCQ49364393-AE871559-F264-47EC-9C94-02AC0F29AC3BQ51331396-510627FA-7C0D-48D5-9126-96BBBF45138EQ55053748-9B75E15E-AB8D-4C7E-8D79-74A6D48B7974
P2860
description
2006 nî lūn-bûn
@nan
2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Interpreting Cancer Trends
@ast
Interpreting Cancer Trends
@en
Interpreting Cancer Trends
@en-gb
Interpreting Cancer Trends
@nl
type
label
Interpreting Cancer Trends
@ast
Interpreting Cancer Trends
@en
Interpreting Cancer Trends
@en-gb
Interpreting Cancer Trends
@nl
altLabel
Interpreting cancer trends
@en
prefLabel
Interpreting Cancer Trends
@ast
Interpreting Cancer Trends
@en
Interpreting Cancer Trends
@en-gb
Interpreting Cancer Trends
@nl
P2093
P2860
P356
P1476
Interpreting Cancer Trends
@en
P2093
P2860
P356
10.1196/ANNALS.1371.048
P407
P577
2006-09-01T00:00:00Z